Celiac disease (CD) treatment requires a gluten-free diet (GFD), although alternative approaches have been proposed. Modification of gliadin peptides using microbial transglutaminase (mTG) inhibits their ability to induce immune response in vitro. Our aim was to evaluate the safety of mTG-modified wheat flour ingestion in CD patients. Twenty-one CD patients in remission were randomized to receive mTG-modified (n=11) or unmodified (n=10) wheat flour rusks, in double-blind fashion. Monthly, patients completed a symptom questionnaire. Serum anti-tTG, EMA and creatinine levels were monitored. At baseline and after 90days, serum anti-actin antibodies (AAA) were measured and upper endoscopy was performed. Data were analyzed by non-parametric tests. 7/11 patients eating modified rusks and 7/10 patients receiving unmodified rusks completed the study. At baseline, all patients showed negative serum anti-tTG and EMA results. At the end, 2/7 (28.6%) patients ingesting modified and 4/7 (57.1%) patients taking unmodified rusks presented positive serum anti-tTG and EMA results. Creatinine results were unmodified. Moreover, 1/7 (14.3%) patients ingesting modified and 4/7 (57.1%) patients taking unmodified rusks presented villous atrophy. In patients who received unmodified rusks, the AAA levels increased significantly and duodenal anti-tTG levels appeared higher than those measured in patients who ate modified rusks. Abdominal swelling, bloating and nausea were more severe in patients ingesting unmodified rusks than those taking modified rusks. Our results may support larger clinical trials to confirm the enzymatic treatment of wheat flour as an alternative to GFD. Clinicaltrials.gov registration no: NCT02472119.

The effects of modified versus unmodified wheat gluten administration in patients with celiac disease / Marino, Mariacatia; Casale, Rossella; Borghini, Raffaele; Di Nardi, Sara; Donato, Giuseppe; Angeloni, Antonio; Moscaritolo, Salvatore; Grasso, Lorenza; Mazzarella, Giuseppe; DI TOLA, Marco; Rossi, Mauro; Picarelli, Antonio. - In: INTERNATIONAL IMMUNOPHARMACOLOGY. - ISSN 1567-5769. - 47:(2017), pp. 1-8. [10.1016/j.intimp.2017.03.012]

The effects of modified versus unmodified wheat gluten administration in patients with celiac disease

MARINO, MARIACATIA;CASALE, ROSSELLA;BORGHINI, RAFFAELE;DONATO, Giuseppe;ANGELONI, Antonio;DI TOLA, MARCO;PICARELLI, Antonio
2017

Abstract

Celiac disease (CD) treatment requires a gluten-free diet (GFD), although alternative approaches have been proposed. Modification of gliadin peptides using microbial transglutaminase (mTG) inhibits their ability to induce immune response in vitro. Our aim was to evaluate the safety of mTG-modified wheat flour ingestion in CD patients. Twenty-one CD patients in remission were randomized to receive mTG-modified (n=11) or unmodified (n=10) wheat flour rusks, in double-blind fashion. Monthly, patients completed a symptom questionnaire. Serum anti-tTG, EMA and creatinine levels were monitored. At baseline and after 90days, serum anti-actin antibodies (AAA) were measured and upper endoscopy was performed. Data were analyzed by non-parametric tests. 7/11 patients eating modified rusks and 7/10 patients receiving unmodified rusks completed the study. At baseline, all patients showed negative serum anti-tTG and EMA results. At the end, 2/7 (28.6%) patients ingesting modified and 4/7 (57.1%) patients taking unmodified rusks presented positive serum anti-tTG and EMA results. Creatinine results were unmodified. Moreover, 1/7 (14.3%) patients ingesting modified and 4/7 (57.1%) patients taking unmodified rusks presented villous atrophy. In patients who received unmodified rusks, the AAA levels increased significantly and duodenal anti-tTG levels appeared higher than those measured in patients who ate modified rusks. Abdominal swelling, bloating and nausea were more severe in patients ingesting unmodified rusks than those taking modified rusks. Our results may support larger clinical trials to confirm the enzymatic treatment of wheat flour as an alternative to GFD. Clinicaltrials.gov registration no: NCT02472119.
Alternative celiac disease treatment; Celiac disease; Enzyme-modified wheat flour; Gluten-free diet; Microbial transglutaminase; Immunology and Allergy; Immunology; Pharmacology
01 Pubblicazione su rivista::01a Articolo in rivista
The effects of modified versus unmodified wheat gluten administration in patients with celiac disease / Marino, Mariacatia; Casale, Rossella; Borghini, Raffaele; Di Nardi, Sara; Donato, Giuseppe; Angeloni, Antonio; Moscaritolo, Salvatore; Grasso, Lorenza; Mazzarella, Giuseppe; DI TOLA, Marco; Rossi, Mauro; Picarelli, Antonio. - In: INTERNATIONAL IMMUNOPHARMACOLOGY. - ISSN 1567-5769. - 47:(2017), pp. 1-8. [10.1016/j.intimp.2017.03.012]
File allegati a questo prodotto
File Dimensione Formato  
Marino_Effects-modified-versus_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 898.88 kB
Formato Adobe PDF
898.88 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/958001
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact